Current Atherosclerosis Reports最新文献_第3页

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions.

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-02-06 DOI: 10.1007/s11883-025-01276-0

Melody Hermel, Abdul Mannan Khan Minhas, Colin Hinkamp, Maha Inam, Nikitha Murthy, Zohar Chai, Vashma Junaid, Adeel Khoja, Sana Sheikh, Leandro Slipczuk, Elizabeth Vaughan, Sandeep Mehta, Elizabeth Epstein, Salim S Virani

{"title":"Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions.","authors":"Melody Hermel, Abdul Mannan Khan Minhas, Colin Hinkamp, Maha Inam, Nikitha Murthy, Zohar Chai, Vashma Junaid, Adeel Khoja, Sana Sheikh, Leandro Slipczuk, Elizabeth Vaughan, Sandeep Mehta, Elizabeth Epstein, Salim S Virani","doi":"10.1007/s11883-025-01276-0","DOIUrl":"https://doi.org/10.1007/s11883-025-01276-0","url":null,"abstract":"Purpose of review: Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions.Recent finding: Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"30"},"PeriodicalIF":5.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women.

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-28 DOI: 10.1007/s11883-025-01275-1

Julie A E van Oortmerssen, Janneke W C M Mulder, Marte F van der Bijl, Ruben J M Mijnster, Maryam Kavousi, Jeanine E Roeters van Lennep

{"title":"Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women.","authors":"Julie A E van Oortmerssen, Janneke W C M Mulder, Marte F van der Bijl, Ruben J M Mijnster, Maryam Kavousi, Jeanine E Roeters van Lennep","doi":"10.1007/s11883-025-01275-1","DOIUrl":"10.1007/s11883-025-01275-1","url":null,"abstract":"Purpose of review: The purpose of this review is to provide an overview of the current status of lipid-lowering therapy utilization and lipid goal attainment in women. We focus on lipid-lowering therapy in individuals with and without established atherosclerotic cardiovascular disease, as well as familial hypercholesterolemia. Additionally, this review aims to explore the underlying mechanisms driving these sex differences and to identify existing knowledge gaps in this area.Recent findings: Despite the proven efficacy of lipid-lowering therapy in both sexes, real-world studies indicate that women with comparable risk profiles are less likely than men to receive these treatments. Furthermore, women who are prescribed statins typically receive lower-intensity regimens than men and are less likely to achieve guideline-recommended low-density lipoprotein cholesterol goals. Despite advancements in lipid-lowering therapies, women compared to men, are systematically undertreated. This difference is influenced by patient-related, physician-related, and societal factors.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"29"},"PeriodicalIF":5.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exposomic Determinants of Atherosclerosis: Recent Evidence. 动脉粥样硬化的暴露性决定因素：最新证据。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-22 DOI: 10.1007/s11883-025-01274-2

Omar Hahad, Usman Sagheer, Khurram Nasir, Marin Kuntic, Andreas Daiber, Ana Navas-Acien, Kai Chen, Sanjay Rajagopalan, Sadeer Al-Kindi

{"title":"Exposomic Determinants of Atherosclerosis: Recent Evidence.","authors":"Omar Hahad, Usman Sagheer, Khurram Nasir, Marin Kuntic, Andreas Daiber, Ana Navas-Acien, Kai Chen, Sanjay Rajagopalan, Sadeer Al-Kindi","doi":"10.1007/s11883-025-01274-2","DOIUrl":"https://doi.org/10.1007/s11883-025-01274-2","url":null,"abstract":"Purpose of review: The exposome refers to the total environmental exposures a person encounters throughout life, and its relationship with human health is increasingly studied. This non-systematic review focuses on recent research investigating the effects of environmental factors-such as air pollution, noise, greenspace, neighborhood walkability, and metallic pollutants-on atherosclerosis, a major cause of cardiovascular disease.Recent findings: Studies show that long-term exposure to airborne particulate matter can impair endothelial function and elevate adhesion molecule levels, leading to vascular damage. Nighttime traffic noise also negatively impacts endothelial health. On the other hand, living in areas with more greenspace and better neighborhood walkability is linked to reduced arterial stiffness, suggesting protective cardiovascular effects. Mechanisms involved include oxidative stress, inflammation, and sympathetic activation from air pollution and noise. Metallic pollutants, including lead, cadmium, and arsenic, are linked to early signs of atherosclerosis through mechanisms involving oxidative stress. However, the effects of specific pollutants and their interactions remain incompletely understood. There is a growing need to mitigate harmful environmental exposures, such as air pollution and noise, while promoting beneficial ones like greenspace, to improve cardiovascular health. Emerging technologies like remote sensing and artificial intelligence can help further our understanding of how the exposome influences cardiovascular outcomes. More research is necessary to clarify the impact of specific pollutants as well as their interactions and how they contribute to atherosclerosis.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"28"},"PeriodicalIF":5.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk. 妊娠并发症与动脉粥样硬化性心血管疾病的长期风险

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-20 DOI: 10.1007/s11883-024-01273-9

Soniya V Rabadia, Sarah Heimberger, Natalie A Cameron, Negeen Shahandeh

{"title":"Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk.","authors":"Soniya V Rabadia, Sarah Heimberger, Natalie A Cameron, Negeen Shahandeh","doi":"10.1007/s11883-024-01273-9","DOIUrl":"10.1007/s11883-024-01273-9","url":null,"abstract":"Purpose of review: Discuss the relationship between pregnancy complications and long-term atherosclerotic cardiovascular disease (ASCVD) risk.Recent findings: A large body of research confirms an association between pregnancy complications and increased short and long-term ASCVD risk and seeks to understand mechanisms for these associations. Social determinants of health continue to have a critical impact on the prevalence of adverse pregnancy outcomes (APOs) and long term ASCVD risk. Of the APOs, hypertensive disorders of pregnancy (HDP) are associated with the highest ASCVD risk. Additionally, recent research shows an association between APOs and microvascular coronary heart disease. APOs are associated with increased risk of ASCVD, however there is conflicting evidence on whether there is a causal relationship between APOs and ASCVD or if APOs are simply a marker of ASCVD risk. Current ASCVD risk models do not incorporate a history of APOs, therefore it is imperative that healthcare providers take a reproductive health history and account for pregnancy complications when counseling patients on long-term cardiovascular risk. Non-invasive modalities such as coronary artery calcium scoring can be considered as an adjunct, but further research is warranted to determine which patients would benefit most.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"27"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From Genetic Findings to new Intestinal Molecular Targets in Lipid Metabolism. 从遗传学发现到脂质代谢的肠道新分子靶点。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-11 DOI: 10.1007/s11883-024-01264-w

Cédric Le May, Simon Ducheix, Bertrand Cariou, Antoine Rimbert

{"title":"From Genetic Findings to new Intestinal Molecular Targets in Lipid Metabolism.","authors":"Cédric Le May, Simon Ducheix, Bertrand Cariou, Antoine Rimbert","doi":"10.1007/s11883-024-01264-w","DOIUrl":"10.1007/s11883-024-01264-w","url":null,"abstract":"Purpose of review: While lipid-lowering therapies demonstrate efficacy, many patients still contend with significant residual risk of atherosclerotic cardiovascular diseases (ASCVD). The intestine plays a pivotal role in regulating circulating lipoproteins levels, thereby exerting influence on ASCVD pathogenesis. This review underscores recent genetic findings from the last six years that delineate new biological pathways and actors in the intestine which regulate lipid-related ASCVD risk.Recent findings: Specifically, we detail the role of LIMA1 in cholesterol absorption within enterocytes, the function of PLA2G12B in the expansion and lipidation of chylomicrons, the involvement of SURF4 in lipoprotein secretion, and the discovery of a gut-derived hormone named CHOLESIN that modulates cholesterol homeostasis through GPR146 via a gut-liver crosstalk. We further discuss the potential of these newly identified genes and pathways as novel targets for pharmaceutical intervention. Newly identified genetic and intestinal molecular mechanisms offer promising opportunities for preventing and treating ASCVD, but careful evaluation and further research are needed to optimize their clinical application.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"26"},"PeriodicalIF":5.7,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142963973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field. Inclisiran，在拥挤的治疗领域出现一种新药物的原因。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-09 DOI: 10.1007/s11883-024-01271-x

Francesco Di Giacomo-Barbagallo, Natalia Andreychuk, Roberto Scicali, Ana Gonzalez-Lleó, Salvatore Piro, Lluis Masana, Daiana Ibarretxe

{"title":"Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field.","authors":"Francesco Di Giacomo-Barbagallo, Natalia Andreychuk, Roberto Scicali, Ana Gonzalez-Lleó, Salvatore Piro, Lluis Masana, Daiana Ibarretxe","doi":"10.1007/s11883-024-01271-x","DOIUrl":"10.1007/s11883-024-01271-x","url":null,"abstract":"Purpose of the review: A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.Recent findings: Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48 h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies. Inclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"25"},"PeriodicalIF":5.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Debate: Lipid-lowering Therapies and Diabetes Development. 辩论：降脂疗法和糖尿病的发展。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-08 DOI: 10.1007/s11883-024-01270-y

Julia Brandts, Dirk Müller-Wieland

{"title":"Debate: Lipid-lowering Therapies and Diabetes Development.","authors":"Julia Brandts, Dirk Müller-Wieland","doi":"10.1007/s11883-024-01270-y","DOIUrl":"10.1007/s11883-024-01270-y","url":null,"abstract":"Purpose of review: This review explores the relationship between lipid-lowering therapies, particularly statins, and the risk of new-onset diabetes (NOD). It examines the underlying mechanisms and evaluates whether other lipid-lowering agents present similar risks.Recent findings: Recent meta-analyses further underscore a dose-dependent increase in NOD risk with statin therapy, particularly with high-intensity statins. In contrast to other LDL-cholesterol lowering drugs and their impact on lipid metabolism in the liver, genetic and experimental studies indicate that statins may impair insulin secretion through various mechanisms, including alterations in small G protein function, calcium signaling, and cholesterol homeostasis in pancreatic beta cells. This might contribute to the increased risk of NOD. Statins effectively reduce cardiovascular events but increase the risk of NOD, potentially via intracellular pathways affecting liver and beta-cell function. Despite the cardiovascular benefits of statins, personalized treatment strategies and alternative lipid-lowering therapies may offer safer options for patients at risk of diabetes, potentially shaping future clinical guidelines and therapeutic approaches.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"24"},"PeriodicalIF":5.7,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Retinal Imaging Including Fundoscopy, OCT, and OCTA for Cardiovascular Risk Stratification and the Detection of Subclinical Atherosclerosis. 视网膜成像包括眼底镜、OCT和OCTA在心血管危险分层和亚临床动脉粥样硬化检测中的应用。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-07 DOI: 10.1007/s11883-024-01268-6

Joseph Colcombe, Elena Solli, Alexis Kaiser, Isha Ranadive, Swathi Bolneni, Jeffrey Berger, Michael Garshick, Yasha Modi

{"title":"The Use of Retinal Imaging Including Fundoscopy, OCT, and OCTA for Cardiovascular Risk Stratification and the Detection of Subclinical Atherosclerosis.","authors":"Joseph Colcombe, Elena Solli, Alexis Kaiser, Isha Ranadive, Swathi Bolneni, Jeffrey Berger, Michael Garshick, Yasha Modi","doi":"10.1007/s11883-024-01268-6","DOIUrl":"10.1007/s11883-024-01268-6","url":null,"abstract":"Purpose of review: Cardiovascular disease (CVD) is a leading cause of preventable morbidity and mortality globally, and retinal imaging modalities (old and new) are being explored as noninvasive tools to predict latent atherosclerosis and cardiovascular disease. This review focuses on the emerging promise of fundoscopy, optical coherence tomography (OCT), and optical coherence tomography angiography (OCTA) in CVD prognostication.Recent findings: High-quality studies have established the utility of vessel-based parameters and discrete conditions diagnosable via fundoscopy in subclinical atherosclerosis detection or CVD prediction. Recent research shows OCT measurements of different retinal layers and specific imaging findings (such as retinal ischemic perivascular lesions) are widely accessible and objective biomarkers for incipient CVD and ensuing risk. Myriad OCTA metrics appear to reliably inform on current CVD burden and cardiovascular risk. Fundoscopy, OCT, and OCTA all have a growing body of literature supporting their utility as adjuncts in CVD prediction and risk stratification.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"23"},"PeriodicalIF":5.7,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Homozygous Familial Hypercholesterolemia Treatment: New Developments. 纯合子家族性高胆固醇血症治疗：新进展。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2025-01-03 DOI: 10.1007/s11883-024-01269-5

Dirk J Blom, A David Marais, Frederick J Raal

{"title":"Homozygous Familial Hypercholesterolemia Treatment: New Developments.","authors":"Dirk J Blom, A David Marais, Frederick J Raal","doi":"10.1007/s11883-024-01269-5","DOIUrl":"10.1007/s11883-024-01269-5","url":null,"abstract":"Purpose of review: Homozygous familial hypercholesterolaemia (HoFH) is characterized by marked elevation of low-density lipoprotein cholesterol (LDLC) and premature atherosclerotic cardiovascular disease. This is a review of novel pharmacological therapies to lower LDLC in patients with HoFH.Recent findings: Novel therapies can be broadly divided by whether their efficacy is dependent or independent of residual low-density lipoprotein receptor (LDLR) function. Novel LDLR dependent therapies that reduce proprotein subtilisin kexin type 9 levels include monoclonal antibodies (alirocumab and evolocumab) and a small inhibitory RNA (inclisiran). LDLC reductions are highly variable and depend on residual LDLR function. Microsomal triglyceride inhibitors (lomitapide) and therapies that reduce angiopoietin like factor 3 (evinacumab and zodasiran) both reduce LDLC by approximately 50%, irrespective of residual LDLR function. Most patients with HoFH require multiple therapies to achieve LDLC targets. Better LDLC control with LDLR independent therapies is likely to improve the outlook for patients with HoFH while at the same time reducing the need for other therapies such as apheresis or hepatic transplantation.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"22"},"PeriodicalIF":5.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statin therapy in primary and secondary cardiovascular disease prevention. 他汀类药物在原发性和继发性心血管疾病预防中的应用。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-30 DOI: 10.1007/s11883-024-01265-9

Rodis D Paparodis, Dimitra Bantouna, Sarantis Livadas, Nicholas Angelopoulos

{"title":"Statin therapy in primary and secondary cardiovascular disease prevention.","authors":"Rodis D Paparodis, Dimitra Bantouna, Sarantis Livadas, Nicholas Angelopoulos","doi":"10.1007/s11883-024-01265-9","DOIUrl":"https://doi.org/10.1007/s11883-024-01265-9","url":null,"abstract":"Purpose of review: Atherosclerotic cardiovascular disease (ASCVD) is one of the most common causes of death globally and the leading one in the US. Elevated low-density lipoprotein (LDL) cholesterol is one of the main modifiable disease risk factors and statin therapies have been extensively studied in that regard. The present work presents the clinical trials derived evidence supporting the use of statins in primary and secondary cardiovascular disease prevention.Recent findings: Statins are a major moderator of hepatic LDL cholesterol output, effectively reducing serum LDL cholesterol concentrations, in a dose-dependent manner. Their use as a single agent or in combination with other treatment modalities (ezetimibe, PCSK9 inhibitors etc.) has been proven to prevent ASCVD events and reduce cardiovascular disease incidence and mortality substantially. Their use is warranted as a first line agent in all secondary prevention patients, as well as those in primary prevention at high or very high risk for ASCVD events and based on the presence of specific modifiers, even in selected cases at moderate ASCVD risk. Their potency and dose should be tailored to the individual's cardiovascular risk and the tolerance to their potential adverse effects in order to achieve the guidelines-directed LDL goals. Statin therapies are the mainstay of therapy for ASCVD risk reduction and should be initiated in all patients at high enough of a risk, to reduce event rates, morbidity and mortality.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"21"},"PeriodicalIF":5.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0